The VHL protein, encoded by the VHL tumor suppressor gene, acts as the cell’s primary oxygen-level manager. Its central job is tagging a family of transcription factors called hypoxia-inducible factors (HIFs) for destruction when oxygen is plentiful. When VHL is missing or broken, HIF accumulates and switches on genes that drive blood vessel growth, metabolic shifts, and cell survival signals, creating conditions that fuel tumor development. This mechanism is so central to one form of kidney cancer that roughly 90% of sporadic clear cell renal cell carcinomas carry VHL mutations, and the discovery of VHL’s oxygen-sensing role helped earn the 2019 Nobel Prize in Physiology or Medicine.
How VHL Controls the Oxygen-Sensing Switch
Every cell in your body needs to respond to fluctuations in oxygen. When oxygen is normal, enzymes called prolyl hydroxylases chemically modify the HIF-alpha subunits by adding a hydroxyl group to specific proline residues. This small chemical tag acts like a flag: it creates a binding site that VHL recognizes.1PubMed Central. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia VHL grabs the hydroxylated HIF-alpha and, working as part of a larger molecular machine, attaches small protein tags called ubiquitin to it. Those ubiquitin chains mark HIF-alpha for rapid destruction by the cell’s protein-recycling system.2PubMed Central. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein
The recognition step is remarkably precise. VHL binds a short stretch of HIF-alpha only when a conserved proline in that stretch has been hydroxylated.3PubMed. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing When oxygen drops, the prolyl hydroxylases can no longer do their work because they need molecular oxygen as a co-substrate. Without the hydroxyl tag, VHL cannot recognize HIF-alpha, so HIF-alpha accumulates, enters the nucleus, and turns on hundreds of genes involved in adapting to low oxygen. These include genes for blood vessel formation (angiogenesis), glucose metabolism, red blood cell production, and cell survival. Under normal conditions, this is a finely tuned and temporary response. The trouble starts when VHL itself is permanently lost.
The Molecular Machine VHL Builds
VHL does not work alone. It assembles into a multi-protein complex that functions as an E3 ubiquitin ligase, essentially a molecular tagging machine. VHL binds directly to two partner proteins, Elongin C and Elongin B, forming what researchers call the VBC complex.4PubMed. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function This trimeric unit then recruits a scaffold protein called Cullin 2 and a small RING-domain protein called Rbx1 to complete the full E3 ligase assembly.5PubMed Central. VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis Structural studies have shown that specific residues in VHL’s BC box and cullin box make contact with Cullin 2 through a combination of hydrophobic packing and salt-bridge interactions, locking the assembly together.6Structure. Insights into Cullin-RING E3 Ubiquitin Ligase Recruitment: Structure of the VHL-EloBC-Cul2 Complex
VHL itself contributes two key surfaces. One binds Elongin C and is a frequent hotspot for cancer-causing mutations. A separate surface on VHL serves as the docking site for hydroxylated HIF-alpha. Cancer mutations tend to cluster in one or both of these patches, either wrecking VHL’s ability to join the E3 ligase complex or destroying its grip on HIF-alpha.4PubMed. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function Either way, HIF escapes destruction.
Von Hippel-Lindau Disease
People who inherit one defective copy of the VHL gene develop von Hippel-Lindau disease, a hereditary cancer syndrome that affects roughly 1 in 36,000 births. If the remaining good copy is lost or silenced in a given tissue, that tissue loses VHL function entirely and becomes susceptible to tumor formation. The syndrome leads to a distinctive constellation of tumors and cysts across multiple organs.
Hemangioblastomas, benign but problematic vascular tumors, are the hallmark. They develop in the central nervous system in about 60 to 80% of patients and in the retina in about 70%.7Applied Radiology. Von Hippel-Lindau Syndrome Clear cell renal cell carcinoma is the most dangerous manifestation, occurring in up to 70% of patients by age 60 and representing the leading cause of death in VHL disease.8Human Molecular Genetics. Genotype–phenotype correlation in von Hippel-Lindau syndrome Pancreatic cysts and neuroendocrine tumors appear in roughly 42% of patients. Pheochromocytomas, tumors of the adrenal glands that can cause dangerous spikes in blood pressure, affect about 30%.7Applied Radiology. Von Hippel-Lindau Syndrome Rarer manifestations include endolymphatic sac tumors in the inner ear, which can cause hearing loss and tinnitus, found in up to 15% of affected individuals.
The type of VHL mutation a person carries shapes which tumors are most likely to develop. A study of 573 individuals with VHL disease found that missense mutations (single amino acid swaps) are more strongly associated with pheochromocytoma, while nonsense or frameshift mutations (which effectively destroy the protein) lead to earlier disease onset and higher rates of retinal tumors and kidney cancer.9PubMed. Genotype-phenotype correlations in von Hippel-Lindau disease Further refinement has shown that the specific location of a missense mutation matters. Mutations that affect the HIF-alpha binding surface of VHL carry different tumor risks than those affecting VHL’s structural core. In particular, missense mutations outside the HIF-binding site are associated with a higher risk of pheochromocytoma but a lower risk of kidney cancer and pancreatic tumors, and those patients tend to have better overall survival compared to patients whose mutations directly disrupt HIF binding.10PubMed. Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-α binding site in VHL protein These genotype-phenotype patterns guide how aggressively physicians screen for specific tumors in affected families.
VHL Loss in Sporadic Kidney Cancer
VHL disease is rare, but the VHL gene is relevant to a much larger population. Clear cell renal cell carcinoma is the most common type of kidney cancer, and about 90% of advanced cases involve mutations in VHL that were acquired during life rather than inherited.11PubMed Central. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation These somatic mutations can happen through direct changes to the DNA sequence, loss of the chromosomal region carrying the gene, or epigenetic silencing through promoter methylation.12PubMed Central. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy
The epigenetic route is worth understanding because it highlights how a gene can be silenced without any change to the DNA letters themselves. A region near the start of the VHL gene, known as a CpG island, can become heavily decorated with methyl groups. This chemical modification effectively shuts the gene off so the cell no longer makes VHL protein. Early research found this methylation mechanism in about 19% of renal tumors examined, and in every case the VHL gene was completely silent despite having no physical mutation in some of those tumors.13PubMed. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma A larger analysis of 470 sporadic clear cell renal tumors found VHL inactivation through sequence changes or promoter methylation in about 87% of cases.14PLOS Genetics. Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors Regardless of the mechanism, the downstream consequence is the same: HIF accumulates, VEGF and other growth-promoting signals rise, and the tumor develops a rich blood supply.
Beyond Oxygen Sensing
While the HIF-degradation role gets the most attention, VHL has jobs that have nothing to do with oxygen levels. One of the most clearly established is its regulation of fibronectin, a protein that forms a structural scaffold outside cells. VHL promotes fibronectin production at the transcription level, and this effect persists regardless of how much oxygen is around, making it a truly HIF-independent function.15PubMed. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL Studies in developing embryos have shown that when VHL is absent from endothelial cells (the cells lining blood vessels), the surrounding fibronectin scaffold fails to assemble properly, leading to defective blood vessel development.16PubMed Central. pVHL function is essential for endothelial extracellular matrix deposition
This matters because it means VHL loss does not only flood cells with growth signals through HIF. It also disorganizes the physical environment around cells, potentially making it easier for tumor cells to invade surrounding tissue. Researchers continue to investigate additional HIF-independent roles for VHL, but the extracellular matrix connection is the best characterized so far.
How VHL Loss Reshapes the Immune Landscape
Kidney tumors driven by VHL loss do not just grow faster; they also alter the immune environment around them in ways that may help them evade the body’s defenses. Research in animal models has shown that tumors lacking VHL attract large numbers of macrophages, immune cells that can either fight or inadvertently support tumors depending on their programming. In VHL-deficient tumors, these macrophages ramp up their glucose consumption and inflammatory signaling, while the lymphocytes that would normally attack the tumor show reduced activation.5PubMed Central. VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis The same study found that tumors lacking VHL responded more poorly to anti-PD-1 immunotherapy, a drug class that has become a backbone of kidney cancer treatment. This mismatch between an inflammatory but immunosuppressive microenvironment helps explain why clear cell renal cell carcinoma can be resistant to immune checkpoint therapy despite being considered an immunologically “hot” tumor.
VHL loss also drives persistent activation of HIF, which coordinately regulates angiogenesis, metabolic reprogramming, and immune cell interactions in ways that reinforce tumor survival.17PubMed Central. Natural Products in Clear Cell Renal Cell Carcinoma: Rewiring the VHL-HIF Axis, Metabolic Plasticity, and Tumor-Immune Interactions In practice, this means a VHL-deficient tumor simultaneously builds its own blood supply, rewires how it generates energy, and subverts the immune cells that arrive to destroy it.
The Difference Between HIF-1α and HIF-2α
Not all HIF is created equal, and the distinction between HIF-1α and HIF-2α turns out to be clinically important. In clear cell renal cell carcinoma, the two isoforms push in different directions. HIF-1α has properties more consistent with a tumor suppressor, while HIF-2α acts as the main oncogenic driver, promoting tumor growth and spread by activating a different set of target genes.18PubMed Central. Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance Many advanced clear cell renal tumors have lost HIF-1α expression entirely but retain high levels of HIF-2α, suggesting the cancer cells evolved to shed the growth-restraining isoform while keeping the growth-promoting one.
This divergence has evolutionary roots. Across vertebrate species, VHL binds HIF-1α more tightly than HIF-2α, thanks to a single amino acid difference (a methionine-to-threonine substitution) that is conserved across the vertebrate lineage. The implication is that vertebrates evolved a more nuanced oxygen response by allowing the two HIF isoforms to be regulated at different stringencies.19PubMed Central. Evolution of metazoan oxygen-sensing involved a conserved divergence of VHL affinity for HIF1α and HIF2α Cancer exploits this natural gap: when VHL is gone, the less-tightly-controlled HIF-2α is especially free to accumulate and drive tumor progression.
Therapies That Target the VHL-HIF-VEGF Pathway
Understanding VHL’s role has transformed how kidney cancer is treated. The logic runs in a straight line: VHL loss leads to HIF accumulation, HIF switches on VEGF, and VEGF drives blood vessel growth that feeds the tumor. Blocking VEGF signaling should therefore starve the tumor. Multiple drugs targeting VEGF receptors are now approved for advanced clear cell renal cell carcinoma, including agents like tivozanib that selectively inhibit VEGF receptors 1, 2, and 3.20PubMed. Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma These anti-angiogenic drugs were among the first targeted therapies for kidney cancer and remain in wide use.21Nature Medicine. Targeting the HIF2–VEGF axis in renal cell carcinoma
A more recent and more precise strategy attacks the problem further upstream by directly blocking HIF-2α. Belzutifan is a first-in-class HIF-2α inhibitor initially approved for tumors associated with VHL disease. In a clinical trial of VHL disease patients, about 49% with kidney tumors had an objective tumor response after a median follow-up of roughly 22 months. The drug also shrank pancreatic lesions in 77% of patients and central nervous system hemangioblastomas in 30%. All evaluable retinal hemangioblastomas showed improvement.22PubMed Central. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease These results are striking for a single oral drug acting across multiple tumor types in different organs, all unified by the same VHL-HIF mechanism. Belzutifan has since been tested in sporadic clear cell renal cell carcinoma as well, reflecting how deeply VHL biology has shaped the treatment landscape.
Synthetic Lethality and New Drug Targets
Beyond targeting HIF and VEGF directly, researchers are exploiting a concept called synthetic lethality: finding genes that cancer cells need for survival specifically because they have already lost VHL. The idea is that a normal cell can tolerate losing either VHL or a second gene, but losing both is fatal. This approach offers a way to selectively kill VHL-deficient cancer cells while leaving healthy tissue alone.
One promising target is TBK1, a kinase known for its role in immune signaling. Genetically deleting or pharmacologically inhibiting TBK1 specifically killed VHL-deficient kidney cancer cells while leaving VHL-intact cells unharmed.23PubMed Central. TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss Another target is the CDK4/6 pathway. CDK4/6 inhibitors, already approved for breast cancer, showed synthetic lethality with VHL inactivation across human cancer cell lines and even in fruit fly models, suggesting the interaction is deeply conserved. This work supports testing CDK4/6 inhibitors for clear cell renal cell carcinoma, potentially in combination with HIF-2α inhibitors.24PubMed Central. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species Both of these synthetic lethal interactions operate independently of HIF, which is encouraging because it means they could work even in tumors that have found ways to survive despite HIF-2α inhibition.
VHL as a Tool in Drug Design
VHL has found a second life outside of cancer biology as a workhorse component in a new class of drugs called PROTACs (proteolysis-targeting chimeras). A PROTAC is a two-headed molecule: one end grabs a disease-causing protein, the other end recruits an E3 ubiquitin ligase. Once the ligase is close enough, it tags the disease protein with ubiquitin, sending it to the cell’s garbage disposal. VHL is one of the most widely used E3 ligases for this purpose because it is expressed in many tissue types and because researchers have developed well-characterized small molecules that bind to it tightly.25PubMed. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
The appeal of PROTACs is that they can theoretically destroy proteins that are considered “undruggable” by traditional small-molecule inhibitors. Traditional drugs need to block a protein’s active site, but many disease-related proteins lack a suitable pocket for a drug to bind. PROTACs sidestep this problem entirely: they do not need to block the target, just bring it close enough to VHL for tagging. Ongoing medicinal chemistry work has focused on developing more potent VHL-binding components and optimizing the linker chemistry that connects the two ends of the PROTAC. Improved VHL binders have already yielded degraders with significantly better potency compared to earlier designs.26PubMed. Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design Several VHL-based PROTACs are now in clinical trials for cancers and other diseases unrelated to VHL disease itself, making VHL arguably more therapeutically important as a tool than as a direct drug target.
Chuvash Polycythemia and Non-Cancer Effects of VHL Variants
Not every VHL mutation leads to cancer. A specific inherited variant found at high frequency among the Chuvash population of Russia causes a condition called Chuvash polycythemia, in which the body overproduces red blood cells. People with this condition carry two copies of a mildly impaired (hypomorphic) VHL gene. The protein still works, just not well enough to fully suppress HIF signaling, so erythropoietin (the hormone that stimulates red blood cell production) stays chronically elevated. Unlike classic VHL disease, Chuvash polycythemia does not predispose people to tumors, underscoring how the severity and location of a VHL mutation determine whether the outcome is cancer, a blood disorder, or no disease at all. The development of HIF-2α inhibitors like belzutifan has opened the door to treating this polycythemia as well, since the overactive HIF pathway is the root cause in both conditions.
This spectrum of VHL-related disease, from aggressive hereditary cancer syndromes to benign polycythemia, illustrates a broader principle in tumor biology. The same gene can produce wildly different clinical outcomes depending on whether one or both copies are lost, which domain of the protein is affected, and which tissues are involved. VHL is one of the most thoroughly studied examples of this genotype-phenotype complexity, and its biology continues to open new avenues in cancer therapy, drug design, and our basic understanding of how cells sense and respond to their environment.